Display options
Cite
Emon MA, Domingo-Fernández D, Hoyt CT, et al. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC Bioinformatics. 2020;21(1):231doi: 10.1186/s12859-020-03568-5.
Emon, M. A., Domingo-Fernández, D., Hoyt, C. T., & Hofmann-Apitius, M. (2020). PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC bioinformatics, 21(1), 231. https://doi.org/10.1186/s12859-020-03568-5
Emon, Mohammad Asif, et al. "PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures." BMC bioinformatics vol. 21,1 (2020): 231. doi: https://doi.org/10.1186/s12859-020-03568-5
Emon MA, Domingo-Fernández D, Hoyt CT, Hofmann-Apitius M. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures. BMC Bioinformatics. 2020 Jun 05;21(1):231. doi: 10.1186/s12859-020-03568-5. PMID: 32503412; PMCID: PMC7275349.
Copy Download .nbib Format: NLM
Share it on

BMC Bioinformatics. 2020 Jun 05;21(1):231. doi: 10.1186/s12859-020-03568-5.

PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.

BMC bioinformatics

Mohammad Asif Emon, Daniel Domingo-Fernández, Charles Tapley Hoyt, Martin Hofmann-Apitius

Affiliations

  1. Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (Fraunhofer SCAI), 53757, Sankt Augustin, Germany. [email protected].
  2. Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, 53117, Bonn, Germany. [email protected].
  3. Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (Fraunhofer SCAI), 53757, Sankt Augustin, Germany. [email protected].
  4. Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, 53117, Bonn, Germany. [email protected].
  5. Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (Fraunhofer SCAI), 53757, Sankt Augustin, Germany.
  6. Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, 53117, Bonn, Germany.

PMID: 32503412 PMCID: PMC7275349 DOI: 10.1186/s12859-020-03568-5

Abstract

BACKGROUND: During the last decade, there has been a surge towards computational drug repositioning owing to constantly increasing -omics data in the biomedical research field. While numerous existing methods focus on the integration of heterogeneous data to propose candidate drugs, it is still challenging to substantiate their results with mechanistic insights of these candidate drugs. Therefore, there is a need for more innovative and efficient methods which can enable better integration of data and knowledge for drug repositioning.

RESULTS: Here, we present a customizable workflow (PS4DR) which not only integrates high-throughput data such as genome-wide association study (GWAS) data and gene expression signatures from disease and drug perturbations but also takes pathway knowledge into consideration to predict drug candidates for repositioning. We have collected and integrated publicly available GWAS data and gene expression signatures for several diseases and hundreds of FDA-approved drugs or those under clinical trial in this study. Additionally, different pathway databases were used for mechanistic knowledge integration in the workflow. Using this systematic consolidation of data and knowledge, the workflow computes pathway signatures that assist in the prediction of new indications for approved and investigational drugs.

CONCLUSION: We showcase PS4DR with applications demonstrating how this tool can be used for repositioning and identifying new drugs as well as proposing drugs that can simulate disease dysregulations. We were able to validate our workflow by demonstrating its capability to predict FDA-approved drugs for their known indications for several diseases. Further, PS4DR returned many potential drug candidates for repositioning that were backed up by epidemiological evidence extracted from scientific literature. Source code is freely available at https://github.com/ps4dr/ps4dr.

Keywords: Bioinformatics; Drug discovery; Drug repositioning; Multi-omics; Pathways; Software

References

  1. Bioinformatics. 2017 Sep 1;33(17):2784-2786 - PubMed
  2. Nat Rev Genet. 2009 Mar;10(3):184-94 - PubMed
  3. Pigment Cell Melanoma Res. 2017 Jan;30(1):53-62 - PubMed
  4. PLoS One. 2014 Jan 22;9(1):e85891 - PubMed
  5. Sci Transl Med. 2011 Aug 17;3(96):96ra77 - PubMed
  6. Arch Pharm Res. 2010 Oct;33(10):1539-56 - PubMed
  7. PLoS One. 2015 Jul 06;10(7):e0132072 - PubMed
  8. Nature. 2008 Mar 27;452(7186):423-8 - PubMed
  9. Nat Biotechnol. 2013 Dec;31(12):1102-10 - PubMed
  10. Cancer Cell. 2006 Jan;9(1):23-32 - PubMed
  11. PLoS One. 2010 Apr 01;5(4):e9979 - PubMed
  12. Nature. 2009 Nov 12;462(7270):175-81 - PubMed
  13. Bioinformatics. 2015 Sep 15;31(18):3069-71 - PubMed
  14. J Med Chem. 2014 Sep 11;57(17):7160-81 - PubMed
  15. Bioinformatics. 2009 Jan 1;25(1):75-82 - PubMed
  16. Front Syst Neurosci. 2012 Oct 23;6:72 - PubMed
  17. BioData Min. 2018 May 31;11:7 - PubMed
  18. Mol Psychiatry. 2015 Jul;20(7):820-6 - PubMed
  19. Nat Commun. 2014;5:3116 - PubMed
  20. Nucleic Acids Res. 2011 Jul;39(Web Server issue):W492-8 - PubMed
  21. Nucleic Acids Res. 2012 Jan;40(Database issue):D1047-54 - PubMed
  22. Bull Med Libr Assoc. 2000 Jul;88(3):265-6 - PubMed
  23. Expert Opin Investig Drugs. 2009 Apr;18(4):501-8 - PubMed
  24. Mol Cancer Ther. 2013 Dec;12(12):2817-26 - PubMed
  25. Nat Rev Neurosci. 2011 Jul 20;12(8):437-52 - PubMed
  26. Mol Cancer Ther. 2012 Jan;11(1):214-23 - PubMed
  27. J Comput Aided Mol Des. 2015 Feb;29(2):155-63 - PubMed
  28. Cancer Res. 2015 Jan 1;75(1):230-40 - PubMed
  29. Breast Cancer Res. 2014 Mar 11;16(2):R24 - PubMed
  30. Eur J Cancer. 2008 Feb;44(3):419-26 - PubMed
  31. Annu Rev Pharmacol Toxicol. 2014;54:9-26 - PubMed
  32. PLoS Comput Biol. 2010 Feb 05;6(2):e1000662 - PubMed
  33. Chem Biol. 2011 Apr 22;18(4):485-94 - PubMed
  34. Nat Neurosci. 2017 Oct;20(10):1342-1349 - PubMed
  35. Brief Bioinform. 2016 Jan;17(1):2-12 - PubMed
  36. Pharm Res. 2012 Sep;29(9):2499-511 - PubMed
  37. IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):1774-1782 - PubMed
  38. IEEE/ACM Trans Comput Biol Bioinform. 2015 Jul-Aug;12(4):928-37 - PubMed
  39. Oncol Rep. 2019 Jan;41(1):125-132 - PubMed
  40. Nat Commun. 2016 Sep 26;7:12846 - PubMed
  41. PLoS One. 2015 May 06;10(5):e0126082 - PubMed
  42. J Biol Chem. 2006 Dec 29;281(52):40485-92 - PubMed
  43. Nature. 2014 Jul 24;511(7510):421-7 - PubMed
  44. Nucleic Acids Res. 2014 Jul;42(Web Server issue):W449-60 - PubMed
  45. DNA Repair (Amst). 2013 Nov;12(11):1000-6 - PubMed
  46. Nat Rev Drug Discov. 2004 May;3(5):417-29 - PubMed
  47. Anticancer Res. 2008 Jan-Feb;28(1A):45-50 - PubMed
  48. PLoS One. 2012;7(12):e51721 - PubMed
  49. Tumour Biol. 2012 Oct;33(5):1299-306 - PubMed
  50. Cancer Res. 2014 Dec 1;74(23):7037-47 - PubMed
  51. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361 - PubMed
  52. PLoS One. 2015 Mar 24;10(3):e0116477 - PubMed
  53. Cancer Res. 2004 Jul 15;64(14):4912-8 - PubMed
  54. BMC Syst Biol. 2012 Jul 02;6:80 - PubMed
  55. J Cheminform. 2013 Jan 14;5(1):3 - PubMed
  56. PLoS One. 2011;6(12):e28025 - PubMed
  57. Nucleic Acids Res. 2017 Jan 4;45(D1):D985-D994 - PubMed
  58. Brief Bioinform. 2020 Feb 14;: - PubMed
  59. BMC Bioinformatics. 2012 Jan 31;13:20 - PubMed
  60. Scand J Gastroenterol. 2013 May;48(5):602-9 - PubMed
  61. Curr Pharm Des. 2005;11(26):3353-61 - PubMed
  62. Biochem Biophys Res Commun. 2016 Mar 4;471(2):290-5 - PubMed
  63. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  64. Invest New Drugs. 2011 Feb;29(1):161-6 - PubMed
  65. Mol Cancer Ther. 2012 Apr;11(4):1036-47 - PubMed
  66. Trends Pharmacol Sci. 2011 Apr;32(4):242-9 - PubMed
  67. ScientificWorldJournal. 2012;2012:756357 - PubMed
  68. J Mol Med (Berl). 2014 Apr;92(4):373-86 - PubMed
  69. Clin Cancer Res. 2011 Aug 15;17(16):5423-31 - PubMed
  70. Redox Biol. 2016 Aug;8:341-7 - PubMed
  71. Nat Rev Drug Discov. 2015 Jul;14(7):475-86 - PubMed
  72. Cell Signal. 2013 Jan;25(1):308-18 - PubMed
  73. Bioinformatics. 2010 Apr 15;26(8):1112-8 - PubMed
  74. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6 - PubMed
  75. Bioinformatics. 2014 Jun 15;30(12):i185-94 - PubMed
  76. Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655 - PubMed
  77. Oncotarget. 2016 Nov 15;7(46):75551-75560 - PubMed
  78. Mult Scler. 2005 Aug;11(4):425-32 - PubMed
  79. J Biochem Pharmacol Res. 2013 Jun;1(2):84-90 - PubMed
  80. Nucleic Acids Res. 2018 Jan 4;46(D1):D661-D667 - PubMed
  81. Database (Oxford). 2016 Jul 03;2016: - PubMed
  82. Nat Biotechnol. 2012 Apr 10;30(4):317-20 - PubMed
  83. Nat Genet. 2005 Jul;37(7):710-7 - PubMed
  84. Trends Pharmacol Sci. 2016 Oct;37(10):872-881 - PubMed
  85. Mol Cell Neurosci. 2015 Mar;65:52-7 - PubMed
  86. N Engl J Med. 1990 Sep 20;323(12):795-801 - PubMed
  87. Nucleic Acids Res. 2014 Jan;42(Database issue):D1001-6 - PubMed
  88. PLoS One. 2015 Oct 13;10(10):e0140310 - PubMed
  89. Bioinformatics. 2005 Aug 15;21(16):3439-40 - PubMed
  90. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082 - PubMed
  91. Science. 2006 Sep 29;313(5795):1929-35 - PubMed
  92. Adv Exp Med Biol. 2010;709:95-107 - PubMed
  93. Brief Bioinform. 2011 Jul;12(4):303-11 - PubMed
  94. J Neurochem. 2017 Sep;142(5):734-746 - PubMed

Substances

MeSH terms

Publication Types

Grant support